Related Experiment Video
Updated: May 4, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
CAR T cells: driving the road from the laboratory to the clinic
Eleanor J Cheadle1, Hannah Gornall, Vania Baldan
1Clinical and Experimental Immunotherapy Group, Department of Medical Oncology, Institute of Cancer Sciences, The University of Manchester, Manchester Academic Healthcare Science Centre, Manchester, UK; Targeted Therapy Group, Institute of Cancer Sciences, The University of Manchester, Manchester Academic Healthcare Science Centre, Manchester, UK.
Abstract:
Blockbuster antibody therapies have catapulted immune-based approaches to treat cancer into the consciousness of mainstay clinical research. On the back of this, other emerging immune-based therapies are providing great promise. T-cell therapy is one such area where recent trials using T cells genetically modified to express an antibody-based chimeric antigen receptor (CAR) targeted against the CD19 antigen have demonstrated impressive responses when adoptively transferred to patients with advanced chronic lymphocytic leukemia. The general concept of the CAR T cell was devised some 20 years ago. In this relatively short period of time, the technology to redirect T-cell function has moved at pace facilitating clinical translation; however, many questions remain with respect to developing the approach to improve CAR T-cell therapeutic activity and also to broaden the range of tumors that can be effectively targeted by this approach. This review highlights some of the underlying principles and compromises of CAR T-cell technology using the CD19-targeted CAR as a paradigm and discusses some of the issues that relate to targeting solid tumors with CAR T cells.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for treating advanced leukemia by redirecting T cells to target cancer cells. Further research is needed to enhance CAR T-cell effectiveness and expand tumor targeting capabilities.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Antibody therapies have advanced cancer treatment, leading to interest in other immune-based approaches.
- Chimeric antigen receptor (CAR) T-cell therapy represents a promising emerging immune-based treatment.
- CAR T-cell technology, conceptualized 20 years ago, has rapidly advanced towards clinical application.
Purpose of the Study:
- To review the principles and limitations of CAR T-cell technology.
- To use CD19-targeted CAR T-cells as a model for understanding CAR T-cell therapy.
- To discuss challenges in applying CAR T-cell therapy to solid tumors.
Main Methods:
- Review of existing literature on CAR T-cell therapy.
- Analysis of CD19-targeted CAR T-cell trials in chronic lymphocytic leukemia.
- Discussion of principles and compromises in CAR T-cell design and function.
Main Results:
- CAR T-cell therapy, exemplified by CD19-targeted approaches, has shown impressive responses in advanced chronic lymphocytic leukemia.
- Significant progress has been made in translating CAR T-cell technology for clinical use.
- Challenges remain in improving therapeutic efficacy and broadening tumor targeting.
Conclusions:
- CAR T-cell therapy is a rapidly advancing field with demonstrated success in certain hematological malignancies.
- Further development is required to optimize CAR T-cell activity and overcome barriers to targeting solid tumors.
- The CD19-targeted CAR T-cell serves as a valuable paradigm for understanding and improving this therapeutic modality.
